FA
VRNA

Forefront Analytics’s Verona Pharma VRNA Stock Holding History

Forefront Analytics’s Portfolio VRNA Stock Details VRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-13,446
Closed -$138K – 79
2022
Q3 		$138K Sell
13,446
-13,750
-51% -$116K 0.07% 49
2022
Q2 		$112K Sell
27,196
-8,460
-24% -$36.2K 0.05% 50
2022
Q1 		$179K Buy
35,656
+1,550
+5% +$9.02K 0.07% 55
2021
Q4 		$229K Buy
34,106
+950
+3% +$4.85K 0.08% 52
2021
Q3 		$181K Buy
33,156
+17,650
+114% +$103K 0.07% 55
2021
Q2 		$104K Buy
15,506
+1,404
+10% +$9.73K 0.04% 62
2021
Q1 		$118K Buy
+14,102
New +$117K 0.05% 60

Other funds holding VRNA

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

Forefront Analytics's VRNA Position: Q4 2022 in Review

Forefront Analytics sold out of Verona Pharma (VRNA) in Q4 2022, closing a stake of 13,446 shares — an estimated $138K sold.

Forefront Analytics first reported a position in VRNA in Q1 2021 and held it in 7 quarters. The position peaked at $229K in Q4 2021. 88 funds tracked by Wall St. Rank hold VRNA as of Q4 2022.

  • Forefront Analytics reported no remaining Verona Pharma position as of Q4 2022 after selling out during the quarter.
  • Forefront Analytics sold 13,446 Verona Pharma shares in Q4 2022, an estimated $138K.
  • Forefront Analytics first reported a position in Verona Pharma in Q1 2021 and held it in 7 quarters.
  • Forefront Analytics's Verona Pharma position peaked at $229K in Q4 2021.
  • 88 funds tracked by Wall St. Rank held Verona Pharma as of Q4 2022.

Based on Forefront Analytics's 13F filing for Q4 2022, filed 13 Feb 2023.